Chunrong Tao1, Rui Li1, Yuyou Zhu1, Sen Qun1, Pengfei Xu1, Li Wang1, Chao Zhang1, Tianlong Liu1, Jianlong Song1, Wen Sun1, Guoping Wang1, Blaise Baxter2, Adnan Qureshi3, Xinfeng Liu1,4, Raul G Nogueira5, Wei Hu1. 1. Stroke Center and Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. 2. Lehigh Valley Health Network, Allentown, PA, USA. 3. Zeenat Qureshi Stroke Research Center, University of Minnesota-Morris, Morris, MN, USA. 4. Department of Neurology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China. 5. Departments of Neurology and Neurosurgery, UPMC Stroke Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
BACKGROUND AND HYPOTHESIS: Recently, two multicenter randomized controlled trials (RCT) failed to show a significantly beneficial effect of endovascular treatment (EVT) in patients with acute basilar artery occlusion (BAO). However, both trials suffered from equipoise issues which may have hindered the validity of the trial results. Therefore, additional RCT studies are needed to explore the potential benefit of EVT in patients presenting with BAO. STUDY DESIGN: ATTENTION is an investigator-initiated, multicenter, prospective, randomized, controlled clinical trial with open-label treatment and blinded outcome assessment (PROBE) of EVT versus best medical management (BMM). The primary effect parameter is a modified Rankin Score of 0-3 at day 90. DISCUSSION: ATTENTION will provide evidence for the efficacy and safety of EVT in stroke patients within 12 h after BAO. TRIAL REGISTRATION: ClinicalTrials.gov NCT04751708.
BACKGROUND AND HYPOTHESIS: Recently, two multicenter randomized controlled trials (RCT) failed to show a significantly beneficial effect of endovascular treatment (EVT) in patients with acute basilar artery occlusion (BAO). However, both trials suffered from equipoise issues which may have hindered the validity of the trial results. Therefore, additional RCT studies are needed to explore the potential benefit of EVT in patients presenting with BAO. STUDY DESIGN: ATTENTION is an investigator-initiated, multicenter, prospective, randomized, controlled clinical trial with open-label treatment and blinded outcome assessment (PROBE) of EVT versus best medical management (BMM). The primary effect parameter is a modified Rankin Score of 0-3 at day 90. DISCUSSION: ATTENTION will provide evidence for the efficacy and safety of EVT in stroke patients within 12 h after BAO. TRIAL REGISTRATION: ClinicalTrials.gov NCT04751708.
Authors: Kevin Hädrich; Pawel Krukowski; Jessica Barlinn; Matthias Gawlitza; Johannes C Gerber; Volker Puetz; Jennifer Linn; Daniel P O Kaiser Journal: Healthcare (Basel) Date: 2022-08-12